SLC5A2 and heart failure: Sodium-glucose cotransporter 2 inhibitors (SGLT2i), originally developed as antidiabetic drugs, have gained widespread usage owing to their proven ability to ameliorate disease conditions, delay disease progression, and confer positive prognostic effects in patients with heart failure (HF) and chronic kidney disease [1–4].